Dosing Begins in Phase 2 Trial of AL001 in ALS With C9orf72 Mutations

Dosing Begins in Phase 2 Trial of AL001 in ALS With C9orf72 Mutations

305792

Dosing Begins in Phase 2 Trial of AL001 in ALS With C9orf72 Mutations

A first patient has been dosed in a Phase 2 clinical trial testing Alector’s investigational antibody AL001 as a treatment for amyotrophic lateral sclerosis (ALS) associated with C9orf72 mutations. The trial is expected to enroll an estimated 45 ALS patients, who will be randomly assigned to AL001 or a placebo, given every four weeks for 24 weeks (about six months) as an infusion directly into the bloodstream, the company reported in a press release. AL001 will be…

You must be logged in to read/download the full post.